AP2000001977A0 - The process for manufacturing topical opthalmic preparations without systemic effects. - Google Patents

The process for manufacturing topical opthalmic preparations without systemic effects.

Info

Publication number: AP2000001977A0
Authority: AP; ARIPO
Prior art keywords: topical; systemic; preparations; timolol; clonidine
Prior art date: 1999-02-03

Application number

APAP/P/2000/001977A

Other languages

English (en)

Inventor

Bakulesh Mafatlal Khamar

Original Assignee

Bakulesh Mafatlal Khamar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-03

Filing date

2000-02-02

Publication date

2000-12-31

2000-02-02 Application filed by Bakulesh Mafatlal Khamar filed Critical Bakulesh Mafatlal Khamar

2000-12-31 Publication of AP2000001977A0 publication Critical patent/AP2000001977A0/en

Links

230000000699 topical effect Effects 0.000 title abstract 5
238000002360 preparation method Methods 0.000 title abstract 4
230000009885 systemic effect Effects 0.000 title abstract 4
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
229940079593 drug Drugs 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 3
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 abstract 2
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 abstract 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 2
229960002896 clonidine Drugs 0.000 abstract 2
229960004605 timolol Drugs 0.000 abstract 2
206010000087 Abdominal pain upper Diseases 0.000 abstract 1
XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 abstract 1
229930003347 Atropine Natural products 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
206010012735 Diarrhoea Diseases 0.000 abstract 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract 1
229930182566 Gentamicin Natural products 0.000 abstract 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
206010022998 Irritability Diseases 0.000 abstract 1
206010028813 Nausea Diseases 0.000 abstract 1
229930193140 Neomycin Natural products 0.000 abstract 1
206010037660 Pyrexia Diseases 0.000 abstract 1
206010041349 Somnolence Diseases 0.000 abstract 1
208000001871 Tachycardia Diseases 0.000 abstract 1
206010046555 Urinary retention Diseases 0.000 abstract 1
206010047700 Vomiting Diseases 0.000 abstract 1
229960002610 apraclonidine Drugs 0.000 abstract 1
IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 abstract 1
229960000396 atropine Drugs 0.000 abstract 1
229960002537 betamethasone Drugs 0.000 abstract 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 abstract 1
208000006218 bradycardia Diseases 0.000 abstract 1
230000036471 bradycardia Effects 0.000 abstract 1
229960003679 brimonidine Drugs 0.000 abstract 1
229960004484 carbachol Drugs 0.000 abstract 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 abstract 1
230000002612 cardiopulmonary effect Effects 0.000 abstract 1
229960003405 ciprofloxacin Drugs 0.000 abstract 1
230000036461 convulsion Effects 0.000 abstract 1
229960003957 dexamethasone Drugs 0.000 abstract 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
206010013781 dry mouth Diseases 0.000 abstract 1
208000030533 eye disease Diseases 0.000 abstract 1
206010016256 fatigue Diseases 0.000 abstract 1
229960003704 framycetin Drugs 0.000 abstract 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 abstract 1
229960002518 gentamicin Drugs 0.000 abstract 1
230000036543 hypotension Effects 0.000 abstract 1
229960001798 loteprednol Drugs 0.000 abstract 1
YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 abstract 1
238000002483 medication Methods 0.000 abstract 1
230000003547 miosis Effects 0.000 abstract 1
239000003604 miotic agent Substances 0.000 abstract 1
230000008693 nausea Effects 0.000 abstract 1
229960004927 neomycin Drugs 0.000 abstract 1
229940023490 ophthalmic product Drugs 0.000 abstract 1
208000035824 paresthesia Diseases 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1
230000006794 tachycardia Effects 0.000 abstract 1
230000008673 vomiting Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Ophthalmology & Optometry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

APAP/P/2000/001977A 1999-02-03 2000-02-02 The process for manufacturing topical opthalmic preparations without systemic effects. AP2000001977A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN90BO1999 IN185228B (fr)	1999-02-03	1999-02-03
PCT/IN2000/000008 WO2000049990A2 (fr)	1999-02-03	2000-02-02	Procede de production de preparations ophtalmiques a usage local sans effet systemique

Publications (1)

Publication Number	Publication Date
AP2000001977A0 true AP2000001977A0 (en)	2000-12-31

Family

ID=11077485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/2000/001977A AP2000001977A0 (en)	1999-02-03	2000-02-02	The process for manufacturing topical opthalmic preparations without systemic effects.

Country Status (11)

Country	Link
EP (1)	EP1139970A2 (fr)
AP (1)	AP2000001977A0 (fr)
AU (1)	AU4429100A (fr)
BR (1)	BR0004530A (fr)
CA (1)	CA2326690A1 (fr)
EA (1)	EA200000918A1 (fr)
ID (1)	ID28121A (fr)
IL (1)	IL138824A0 (fr)
IN (1)	IN185228B (fr)
WO (1)	WO2000049990A2 (fr)
ZA (1)	ZA200006252B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8858961B2 (en)	2000-07-14	2014-10-14	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
WO2002005853A2 (fr) *	2000-07-14	2002-01-24	Allergan, Inc.	Compositions contenant des composants agonistes alpha-2 adrenergiques
AU2005220199B2 (en) *	2000-07-14	2007-03-08	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
DE10132876A1 (de) *	2001-07-06	2003-01-30	Medproject Pharma Entwicklungs	Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge
US7439241B2 (en)	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
DK1761266T3 (da)	2004-05-25	2013-08-05	Galderma Pharma Sa	Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
EP2329849B1 (fr)	2009-11-18	2015-04-29	Galderma Research & Development	Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire
FR2977493B1 (fr)	2011-07-05	2014-02-14	Galderma Res & Dev	Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
AU2014216112B2 (en) *	2013-02-15	2019-02-21	Allergan, Inc.	Sustained drug delivery implant
WO2014150899A1 (fr) *	2013-03-15	2014-09-25	Chapin Matthew J	Formulations ophtalmiques topiques pour traiter la migraine
WO2016172712A2 (fr)	2015-04-23	2016-10-27	Sydnexis, Inc.	Composition ophtalmique
US9421199B2 (en)	2014-06-24	2016-08-23	Sydnexis, Inc.	Ophthalmic composition
EP3302426A4 (fr)	2015-05-29	2018-12-05	Sydnexis, Inc.	Formulations pharmaceutiques stabilisées de d2o
GB202110420D0 (en) *	2021-07-20	2021-09-01	Rosemont Pharmaceuticals Ltd	Liquid pharmaceutical composition of clonidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6056684B2 (ja) *	1977-11-07	1985-12-11	東興薬品工業株式会社	点眼剤
DD294174A5 (de) *	1990-05-04	1991-09-26	Sigrid Keipert	Ophthalmika mit retardwirkung und ein neues verfahren zu ihrer herstellung
FR2678832B1 (fr) *	1991-07-10	1995-03-17	Europhta Sa Laboratoire	Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.
FR2679773A1 (fr) *	1991-07-30	1993-02-05	Merck Sharp & Dohme	Preparation ophtalmique contenant un agent osmotique acceptable antimicrobien.
DE19614823A1 (de) *	1996-04-15	1997-10-16	Mann Gerhard Chem Pharm Fab	Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge

1999
- 1999-02-03 IN IN90BO1999 patent/IN185228B/en unknown
2000
- 2000-02-02 CA CA002326690A patent/CA2326690A1/fr not_active Abandoned
- 2000-02-02 WO PCT/IN2000/000008 patent/WO2000049990A2/fr not_active Ceased
- 2000-02-02 EA EA200000918A patent/EA200000918A1/ru unknown
- 2000-02-02 AU AU44291/00A patent/AU4429100A/en not_active Abandoned
- 2000-02-02 IL IL13882400A patent/IL138824A0/xx unknown
- 2000-02-02 ID IDW20002252A patent/ID28121A/id unknown
- 2000-02-02 BR BR0004530-6A patent/BR0004530A/pt not_active Application Discontinuation
- 2000-02-02 EP EP00925571A patent/EP1139970A2/fr not_active Withdrawn
- 2000-02-02 AP APAP/P/2000/001977A patent/AP2000001977A0/en unknown
- 2000-11-01 ZA ZA200006252A patent/ZA200006252B/en unknown

Also Published As

Publication number	Publication date
AU4429100A (en)	2000-09-14
ZA200006252B (en)	2001-11-29
WO2000049990A3 (fr)	2001-07-26
ID28121A (id)	2001-05-03
IN185228B (fr)	2000-12-09
EA200000918A1 (ru)	2001-10-22
EP1139970A2 (fr)	2001-10-10
CA2326690A1 (fr)	2000-08-31
IL138824A0 (en)	2001-10-31
WO2000049990A2 (fr)	2000-08-31
BR0004530A (pt)	2001-04-03

Publication	Publication Date	Title
AP2000001977A0 (en)	2000-12-31	The process for manufacturing topical opthalmic preparations without systemic effects.
WO2004071469A3 (fr)	2004-12-29	Methodes d'administration d'un agent dermatologique a un patient
CA2633594C (fr)	2021-10-26	Moyens et procedes pour le traitement de maladies tumorales
US9216167B2 (en)	2015-12-22	Ketorolac tromethamine compositions for treating or preventing ocular pain
AU2003301747A8 (en)	2004-05-25	Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
PL378051A1 (pl)	2006-02-20	Szybko działająca kompozycja farmaceutyczna
CA2460140A1 (fr)	2003-03-27	Compositions de traitement d'un rhume simple
BR0313575A (pt)	2005-06-28	Método de transporte transdermal de produtos farmacêuticos topicamente administrados, veìculo, composição de veìculo, composição farmacêutica e uso de um ou mais complexos de derivados de fosfato de compostos farmaceuticamente aceitáveis lipofìlicos com outros excipientes
WO2004045593A3 (fr)	2004-08-12	Polytherapie anticancereuse au moyen d'un compose anticancereux active par gst et d'un autre traitement anticancereux
WO2007126964A3 (fr)	2007-12-21	Inhibiteurs de kinase
AU2001288460A1 (en)	2002-03-22	Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
AU2003243719A1 (en)	2004-01-06	Topical administration of pharmacologically active bases in the treatment of warts
BR0305628A (pt)	2004-09-08	Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
WO2006093784A3 (fr)	2007-08-16	Antibiotiques, ainsi que combinaisons d'antibiotiques et de formulations d'agents de soulagement symptomatique
El Maalouf et al.	2007	Could we expect to improve survival in small cell lung cancer?
US6444676B1 (en)	2002-09-03	Use of PARP inhibitors in the treatment of glaucoma
WO2001074365A3 (fr)	2002-03-21	Posologie efficace de galantamine reduisant les effets secondaires
WO2005011618A3 (fr)	2005-12-29	Methodes de traitement de dysfonctionnements sexuels masculins et feminins
MX2022013391A (es)	2022-11-30	Pauta posologica para el tratamiento del cancer.
AU2003290015A1 (en)	2004-07-09	Mastitis treatment
WO2001041747A3 (fr)	2002-02-07	Preparation pharmaceutique pour traiter des affections tumorales
WO2003047697A3 (fr)	2003-10-30	Methodes de traitement du cancer utilisant un inhibiteur de farnesyl transferase (fpt) et des agents antineoplasiques
US6663850B2 (en)	2003-12-16	Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
WO2000061171A3 (fr)	2001-01-25	Nouvelles utilisations de la proteine ox2 de mammifere et reactifs associes
MXPA05012826A (es)	2006-02-13	Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen.